B of A Securities Downgrades ProKidney to Neutral, Lowers Price Target to $2
B of A Securities Downgrades ProKidney to Neutral, Lowers Price Target to $2
Bof A證券將ProKidney的評級下調至中性，將目標股價下調至2美元
B of A Securities analyst Jason Gerberry downgrades ProKidney (NASDAQ:PROK) from Buy to Neutral and lowers the price target from $8 to $2.
B of A Securities分析師傑森·格伯裏將ProKidney（納斯達克股票代碼：PROK）的評級從買入下調至中性，並將目標股價從8美元下調至2美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。